When we hear about fatty liver disease, we can often jump to the image of someone who drinks excessive amounts of alcohol. <\/p>\n\n\n\n
But that\u2019s not always the case. In fact, it\u2019s often not the case at all. As you will see in this article below, alcohol is not usually the cause of fatty liver disease. <\/p>\n\n\n\n
Fatty liver disease is on the rise, and it is because of the way we eat and the way we (don\u2019t) move. The good news is that a healthy lifestyle can stave off fatty liver disease. <\/p>\n\n\n\n
Fatty liver disease is the deposition of fat into the liver. Non-alcoholic fatty liver disease is what its name implies. It is fatty liver disease due to factors other than excessive alcohol consumption<\/a>. <\/p>\n\n\n\n Lipid droplets are storages of fat present in all cells. Metabolic imbalances between the creation and degradation of lipid droplets leads to significant fat storage. This is a key feature of liver cells in patients with fatty liver disease.<\/p>\n\n\n\n <\/p>\n\n\n\n Non-alcoholic fatty liver disease encompasses a whole spectrum of liver disorders. These disorders are characterized by the following:<\/p>\n\n\n\n Alcoholic fatty liver disease is the same liver damage as above but happens due to excessive alcohol intake.<\/p>\n\n\n\n Non-alcoholic steatohepatitis involves progressive liver injury. There is also usually a hepatic inflammation present. Fibrosis can also occur as well.<\/p>\n\n\n\n Simple fatty liver is actually not too serious. It is considered a benign condition, and its prognosis is long term.<\/p>\n\n\n\n Acute fatty liver of pregnancy is an obstetric emergency. It involves a liver failure in the mother. It can have complications for both the mother and the fetus. And, it can even result in death. <\/p>\n\n\n\n Pediatric and adolescent non-alcoholic fatty liver disease differs from the adult version of these conditions. They should, therefore, be recognized as different and distinct conditions.<\/p>\n\n\n\n Oddly enough, fatty liver disease often doesn\u2019t have any symptoms at all. In fact, fatty liver disease is often found by accident on blood tests or imaging performed for other reasons. <\/p>\n\n\n\n The blood tests of someone with fatty liver disease will show elevated liver enzymes. This demonstrates that abnormal liver function is occurring. Non-alcoholic liver disease is the most common cause of high liver enzymes. One possible symptom of fatty liver disease is vague upper abdominal pain<\/a>.<\/p>\n\n\n\n Non-alcoholic fatty liver disease occurs when the body can no longer effectively store excess energy in fat tissue. Insulin resistance leads to widespread metabolic disturbances throughout the body. There is an accumulation of triglycerides in the liver. <\/p>\n\n\n\n Insulin resistance<\/a> and extra fats can lead to an increased influx of fats into the liver. This then stimulates the new creation of fats within the liver. This then leads to the accumulation of triglycerides in the liver. Defects in fat utilization via mitochondrial oxidation and fat export can also contribute to the liver’s fat buildup. <\/p>\n\n\n\n Adipocytokine alterations and fat toxicity from saturated fatty acids and fructose may cause liver tissue injury. They do this through pathways involving oxidative and endoplasmic reticulum stress.<\/p>\n\n\n\n Non-alcoholic steatohepatitis results from liver fat toxicity. The key problem here is not the amount of liver fat, but the types of fat molecules that accumulate. Another problem is how these fat molecules are packaged to avoid subcellular injury. <\/p>\n\n\n\n <\/p>\n\n\n\n Cells that are unable to sequester chemically reactive fat molecules experience a mitochondrial injury. They also undergo endoplasmic reticulum stress and autophagy. All of these are processes that can contribute to non-alcoholic steatohepatitis. <\/p>\n\n\n\n Lipotoxicity kills liver cells through a process called apoptosis. Apoptosis is a highly regulated, non-inflammatory form of cell death. Liver cells also die by necrosis, necroptosis, and pyroptosis. These involve mitochondrial injury, oxidative stress, and release of DAMPs (danger-associated molecular patterns). <\/p>\n\n\n\n The danger associated molecular patterns stimulate tolls like receptor 4 (TLR4) and NLRP3 (NOD-like receptor protein 3). These releases a cascade of pro-inflammatory chemokines and cytokines<\/a>. <\/p>\n\n\n\n Lipotoxic liver cell injury attracts inflammatory cells, particularly activated macrophages. These surround ballooned liver cells as crown-like structures. Injured liver cells liberate plasma membrane-derived extracellular vesicles. These tend to circulate in the plasma of people with non-alcoholic steatohepatitis. They are pro-inflammatory.<\/p>\n\n\n\n Metabolic dysfunction<\/a> leads to fat toxicity. This results in a pattern of cellular inflammation in the liver. This is all relevant to liver fibrosis and liver cancer.<\/p>\n\n\n\n Potential risk factors for fatty liver disease include the following:<\/p>\n\n\n\n The prevalence of non-alcoholic fatty liver disease is highest in populations with pre-existing metabolic conditions. <\/p>\n\n\n\n These include obesity and type 2 diabetes. The worldwide prevalence of fatty liver disease is increasing in conjunction with the growing obesity epidemic.<\/p>\n\n\n\n Researchers have also noted a correlation between fatty liver disease and dysbiosis of the gut microbiome. The liver connects to the gut and gastrointestinal system through the portal vein. There is a gut liver axis, and that means gut imbalances can have effects on the liver.<\/p>\n\n\n\n Non-alcoholic fatty liver disease is a spectrum. This spectrum ranges from mild hepatic steatosis to non-alcoholic steatohepatitis. Liver disease is known as a \u201csilent disease,\u201d meaning it can progress over many years to become non-alcoholic steatohepatitis. <\/p>\n\n\n\n Hepatic steatosis can be mild. But if it is happening along with insulin resistance and increased oxidative stress, it may lead to progressive disease.<\/p>\n\n\n\n Non-alcoholic steatohepatitis can lead to liver cell injury and inflammation. It can also result in cirrhosis of the liver, liver failure, and even liver cancer. More severe stages of fatty liver disease may require a liver transplantation. <\/p>\n\n\n\n The most severe stages of fatty liver can result in death. Between one and two-thirds of non-alcoholic steatohepatitis cases progress to liver fibrosis or cirrhosis (liver scarring). Non-alcoholic fatty liver disease is an independent risk factor for heart disease<\/a>. It also leads to an increased risk of death.<\/p>\n\n\n\n The diagnosis of fatty liver disease depends on a variety of assessment tools. These include liver biopsy and radiological liver tests such as ultrasound. It also involves blood tests like liver enzymes. Your doctor will likely perform a physical examination as well.<\/p>\n\n\n\n The gold standard in diagnosis of fatty liver disease is a liver biopsy. There are some limitations to this test, though. It is invasive, expensive, and there have been reports of variability between samples.<\/p>\n\n\n\n New research has shown that serum-based markers of fatty liver disease (such as cytokeratin-18 fragments) offer promise as possible future testing options.<\/p>\n\n\n\n Diagnosis and proper tracking of the progression of fatty liver disease are difficult. This is because fatty liver disease is so complex. The biggest challenge for diagnosticians is finding a non-invasive e way to diagnose non-alcoholic steatohepatitis. <\/p>\n\n\n\n This is because no reliable biomarkers have been found to detect or predict liver inflammation in non-alcoholic fatty liver disease.<\/p>\n\n\n\n <\/p>\n\n\n\n <\/p>\n\n\n\n The treatment of non-alcoholic fatty liver disease revolves around addressing associated metabolic risk factors. It also involves improving insulin resistance through weight loss and exercise.<\/p>\n\n\n\n <\/p>\n\n\n\n The first-line approach for fatty liver disease is lifestyle modification. This includes slow and steady weight loss, improved dietary habits, and increased daily aerobic physical activity. Weight loss is the most effective way to promote liver fat removal. Several controlled studies have shown that lifestyle changes can lead to the desired seven to ten percent weight loss. This percentage of weight loss is associated with reduced liver fat, less fibrosis, and less remission of non-alcoholic steatohepatitis. So, cognitive-behavioral therapy can help in achieving this amount of weight loss. <\/p>\n\n\n\n Even larger effects can be obtained after bariatric surgery-induced weight loss. One study showed that 80% of patients with non-alcoholic fatty liver disease who got bariatric surgery had a resolution of steatohepatitis one year later. Antioxidant therapy can be beneficial in some patients with biopsy-proven fatty liver disease. This includes the use of vitamin E<\/a>. You can also treat fatty liver disease through the gut liver axis. You can do this by using probiotics, prebiotics, and synbiotics. The results of a meta-analysis research study showed that probiotics<\/a> could be helpful in fatty liver disease. Probiotics lowered levels of alanine aminotransferase (AL) and aspartate transaminase (AST). They also decreased total cholesterol and HOMA-IR (homeostasis model assessment of insulin resistance). <\/p>\n\n\n\n When it comes to drug therapies, there is currently no consensus regarding the treatment of fatty liver disease. Treatments targeting the pathophysiological mechanisms of non-alcoholic fatty liver disease exist. <\/p>\n\n\n\n However, these carry some potential risks and are not universally effective. Insulin sensitivity agents, such as pioglitazone<\/a>, show some promise. <\/p>\n\n\n\n They can improve the health of liver cells in patients with non-alcoholic steatohepatitis. However, there is not necessarily the long term benefit of these medications.<\/p>\n\n\n\nTypes of fatty liver disease<\/h2>\n\n\n\n
Non-alcoholic fatty liver disease<\/h3>\n\n\n\n
\n
<\/li>\n\n\n\n
<\/li>\n\n\n\nAlcoholic fatty liver disease<\/h3>\n\n\n\n
Non-alcoholic steatohepatitis<\/h3>\n\n\n\n
Simple hepatic steatosis<\/h3>\n\n\n\n
Acute fatty liver of pregnancy<\/h3>\n\n\n\n
Pediatric and adolescent non-alcoholic fatty liver disease<\/h3>\n\n\n\n
What are the symptoms of fatty liver disease?<\/h2>\n\n\n\n
What causes fatty liver disease?<\/h2>\n\n\n\n
Possible lipotoxic mediators<\/h3>\n\n\n\n
<\/h3>\n\n\n\n
\n
<\/li>\n\n\n\n
<\/li>\n\n\n\n
<\/li>\n\n\n\n
<\/li>\n\n\n\n
<\/li>\n\n\n\nRisk factors<\/h2>\n\n\n\n
\n
<\/li>\n\n\n\n
<\/li>\n\n\n\n
<\/li>\n\n\n\n
<\/li>\n\n\n\n
<\/li>\n\n\n\n
<\/li>\n\n\n\n
<\/li>\n\n\n\n
<\/li>\n\n\n\n
<\/li>\n\n\n\n
<\/li>\n\n\n\n
<\/li>\n\n\n\nStages of fatty liver<\/h2>\n\n\n\n
Diagnosis<\/h2>\n\n\n\n
Methods<\/h3>\n\n\n\n
\n
<\/li>\n<\/ul>\n\n\n\n\n
<\/li>\n<\/ul>\n\n\n\n\n
<\/li>\n<\/ul>\n\n\n\n\n
Treatment<\/h2>\n\n\n\n
Lifestyle changes<\/strong><\/h3>\n\n\n\n
<\/p>\n\n\n\nWeight loss<\/strong><\/h3>\n\n\n\n
<\/p>\n\n\n\nBariatric surgery<\/strong><\/h3>\n\n\n\n
<\/p>\n\n\n\nAntioxidant therapy<\/strong><\/h3>\n\n\n\n
<\/p>\n\n\n\nGut liver axis<\/strong><\/h3>\n\n\n\n